TEW-7197 with Paclitaxel for the Treatment of Metastatic Gastric Cancer
An Open-label, Multicenter Phase Ib/2a Study of TEW-7197 (Vactosertib) Plus Weekly Paclitaxel As Second-line Treatment for Metastatic Gastric Adenocarcinoma
Sponsor: MedPacto, Inc.
Listed as NCT03698825, this PHASE1/PHASE2 trial focuses on Metastatic Gastric Cancer and remains completed. Sponsored by MedPacto, Inc., it has been updated 10 times since 2018, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
10 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE1/PHASE2
-
Jan 2025 — Sep 2025 [monthly]
Completed PHASE1/PHASE2
Status: Unknown → Completed
-
Sep 2024 — Jan 2025 [monthly]
Unknown PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE1/PHASE2
Status: Unknown Status → Unknown · Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Feb 2023 — Jul 2024 [monthly]
Unknown Status PHASE1_PHASE2
Status: Active Not Recruiting → Unknown Status
▶ Show 5 earlier versions
-
Apr 2021 — Feb 2023 [monthly]
Active Not Recruiting PHASE1_PHASE2
Status: Recruiting → Active Not Recruiting
-
Jan 2021 — Apr 2021 [monthly]
Recruiting PHASE1_PHASE2
-
Jun 2020 — Jan 2021 [monthly]
Recruiting PHASE1_PHASE2
Phase: PHASE1 → PHASE1_PHASE2
-
Nov 2019 — Jun 2020 [monthly]
Recruiting PHASE1
-
Nov 2018 — Nov 2019 [monthly]
Recruiting PHASE1
First recorded
Aug 2018
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- MedPacto, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .